Clinical trials
Observational Macular Edema trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 8 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 52 |
| Unknown status | 11 |
| Terminated | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Allergan | 11 |
| Bayer | 5 |
| National Eye Institute (NEI) | 5 |
| Hospital Juarez de Mexico | 3 |
| Medical University of Vienna | 3 |
| St. Franziskus Hospital | 3 |
| Duke University | 2 |
| Kubota Vision Inc. | 2 |
| Retina Institute of Hawaii | 2 |
| Aalborg University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Edema | 75 |
| Retinal Vein Occlusion | 22 |
| Macular Degeneration | 13 |
| Diabetic Retinopathy | 12 |
| Uveitis | 9 |
| Diabetes Mellitus | 5 |
| Epiretinal Membrane | 5 |
| Cataract | 4 |
| Retinal Diseases | 4 |
| Iridocyclitis | 2 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.